Latest news with #AnandChokkavelu
Globe and Mail
30-05-2025
- Business
- Globe and Mail
Is Dollarama Stock Worth the Investment? Here's What the Experts Say.
Explore the exciting world of Dollarama (OTC: DLMAF) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 23, 2025. The video was published on May 30, 2025. Should you invest $1,000 in Dollarama right now? Before you buy stock in Dollarama, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dollarama wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Dan Caplinger has no position in any of the stocks mentioned. Jim Gillies has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
29-05-2025
- Business
- Globe and Mail
Alimentation Couche-Tard: A Strong Player in the Convenience Store Market
Explore the exciting world of Alimentation Couche-Tard (OTC: ANCT.F) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 23, 2025. The video was published on May 29, 2025. Should you invest $1,000 in Alimentation Couche-Tard right now? Before you buy stock in Alimentation Couche-Tard, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alimentation Couche-Tard wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to170%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Dan Caplinger has no position in any of the stocks mentioned. Jim Gillies has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alimentation Couche-Tard. The Motley Fool has a disclosure policy.
Globe and Mail
28-05-2025
- Business
- Globe and Mail
Is Medpace Stock Worth the Hype? Here's What Analysts Think.
Explore the exciting world of Medpace Holdings (NASDAQ: MEDP) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 23, 2025. The video was published on May 27, 2025. Should you invest $1,000 in Medpace right now? Before you buy stock in Medpace, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medpace wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Dan Caplinger has no position in any of the stocks mentioned. Jim Gillies has positions in Medpace. The Motley Fool has positions in and recommends Medpace. The Motley Fool has a disclosure policy.
Globe and Mail
17-05-2025
- Business
- Globe and Mail
Guardant Health: A Promising Player in the Liquid Biopsy Market
Explore the exciting world of Guardant Health (NASDAQ: GH) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 9, 2025. The video was published on May 16, 2025. Should you invest $1,000 in Guardant Health right now? Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,275!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,385!* Now, it's worth noting Stock Advisor 's total average return is967% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy.
Globe and Mail
18-02-2025
- Business
- Globe and Mail
Is This Stock a Next-Gen Digital Forensics Leader?
In this video, Anand Chokkavelu, Travis Hoium, and Lou Whiteman discuss Cellebrite (NASDAQ: CLBT), a key player in digital forensics for law enforcement. They provide ratings and insights on its growth potential, management, and financials, helping you decide if this stock is a worthy investment. *Stock prices used were the prices of Jan. 15, 2025. The video was published on Feb. 17, 2025. Should you invest $1,000 in Cellebrite right now? Before you buy stock in Cellebrite, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cellebrite wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Learn more » *Stock Advisor returns as of February 7, 2025
